Microbiome market is booming, projected to grow from $486M in 2023 to $2.8B by 2030.
Advances in science and tech are driving innovation in diagnostics, therapeutics, and personalized care.
Consumer demand and investment are fueling growth in probiotics, gut health products, and engineered therapies.
The human microbiome industry is entering a transformative phase, shaped by cutting-edge scientific breakthroughs, increasing healthcare needs, and growing public interest. The Human Microbiome Strategic Business Research Report 2024 projects that the global microbiome market will rise dramatically from $486 million in 2023 to $2.8 billion by 2030. Industry leaders such as DuPont de Nemours and Enterome are helping to drive this momentum, signaling substantial opportunities for businesses looking to establish or expand their presence in this field.
This content is part of the PREMMIUM blog on MICK®
SEQUENTIA® BIOTECH SL
Barcelona
+34 930 107 368
* Sending the email implies acceptance of the Privacy Policy.
MICK® is co-founded by the European Union - grant agreement 190195702
European Union Funding H2020 Research and Innovation programme - grant agreement #868117
MICK® does not claim to diagnose, treat, cure, or prevent any disease. The information on the MICK® website is provided for informational purposes only and with the understanding that MICK® is not engaged in rendering medical advice or recommendations. You should not rely on any information on the website to diagnose or treat a health problem or condition or replace consultations with qualified health care professionals to meet your individual needs. Always check with your doctor for answers to your personal medical questions.
Copyright © Sequentia® Biotech 2024
